Hamilton Wealth LLC Acquires 38,916 Shares of Guardant Health, Inc. $GH

Hamilton Wealth LLC boosted its holdings in Guardant Health, Inc. (NASDAQ:GH) by 103.0% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 76,700 shares of the company’s stock after purchasing an additional 38,916 shares during the quarter. Guardant Health comprises 1.4% of Hamilton Wealth LLC’s portfolio, making the stock its 20th largest position. Hamilton Wealth LLC’s holdings in Guardant Health were worth $7,085,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in GH. World Investment Advisors purchased a new stake in shares of Guardant Health in the 4th quarter worth approximately $1,664,000. Orbimed Advisors LLC bought a new position in Guardant Health during the 1st quarter valued at approximately $40,199,000. Capricorn Fund Managers Ltd raised its stake in Guardant Health by 197.8% during the fourth quarter. Capricorn Fund Managers Ltd now owns 107,787 shares of the company’s stock valued at $11,009,000 after buying an additional 71,587 shares during the last quarter. Caxton Associates LLP purchased a new position in Guardant Health during the first quarter valued at $831,000. Finally, Styrax Capital LP boosted its holdings in Guardant Health by 6.5% in the first quarter. Styrax Capital LP now owns 300,000 shares of the company’s stock worth $27,711,000 after acquiring an additional 18,411 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Performance

Shares of GH opened at $161.99 on Monday. The business’s fifty day simple moving average is $143.44 and its two-hundred day simple moving average is $113.42. Guardant Health, Inc. has a 12 month low of $40.35 and a 12 month high of $176.58. The company has a market cap of $21.48 billion, a price-to-earnings ratio of -46.42 and a beta of 1.59.

Key Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Revenue and testing growth exceeded expectations. Second-quarter revenue rose 44% year over year to $335.0 million, above the $314.2 million analyst estimate. Oncology revenue increased 38% to $219.1 million, while oncology test volume climbed 63% to approximately 104,000. Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Positive Sentiment: Guardant raised its 2026 revenue guidance to $1.3 billion-$1.4 billion, compared with consensus around $1.3 billion. The outlook increase signals continued demand for the company’s cancer-screening and precision-oncology tests. Guardant Health hits 52-week high after guidance hike
• Positive Sentiment: JPMorgan raised its price target from $185 to $195 and maintained an “overweight” rating, reinforcing bullish analyst sentiment and suggesting additional potential upside. JPMorgan raises Guardant Health price target
• Neutral Sentiment: Guardant reported a second-quarter adjusted loss of $0.42 per share, compared with a $0.44 loss a year earlier. Reports differed on the consensus comparison, with one estimate showing a modest miss and another indicating a substantial beat. Guardant Health Q2 earnings report
• Negative Sentiment: Profitability remains a concern. Guardant continues to generate quarterly losses, and investor commentary is weighing whether rapidly rising revenue can offset ongoing spending and losses. Does Guardant’s Surging Revenue and Deeper Losses Reframe the Growth Thesis for GH?

Insider Activity

In other news, CEO Helmy Eltoukhy sold 100,000 shares of the company’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the transaction, the chief executive officer directly owned 2,012,919 shares of the company’s stock, valued at $254,231,669.70. This represents a 4.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Meghan V. Joyce sold 10,000 shares of the stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total value of $1,269,800.00. Following the sale, the director directly owned 11,183 shares in the company, valued at $1,420,017.34. This trade represents a 47.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 708,565 shares of company stock valued at $90,556,597. Corporate insiders own 5.60% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on GH shares. JPMorgan Chase & Co. increased their target price on Guardant Health from $185.00 to $195.00 and gave the stock an “overweight” rating in a research note on Friday. Stifel Nicolaus set a $180.00 price target on Guardant Health in a research report on Friday. Bank of America upped their price target on shares of Guardant Health from $135.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, July 6th. UBS Group set a $150.00 price objective on shares of Guardant Health in a research report on Wednesday, June 24th. Finally, Royal Bank Of Canada raised their price objective on shares of Guardant Health from $185.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and a consensus price target of $179.82.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.